Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 4:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 20,701 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Conditions
Rheumatoid Arthritis
Interventions
GP2013, MabThera, Rituxan
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Lexington, Kentucky • Cumberland, Maryland + 13 more
Conditions
Leukemia, Lymphoma
Interventions
bispecific antibody 4G7xH22, sargramostim
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Lebanon, New Hampshire
Completed Phase 2 Interventional Results available

Fibrin Sealant for the Sealing of Dura Sutures

NCT00681824
Conditions
Pathological Processes in the Posterior Fossa, Dura Defects
Interventions
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Standard of care
Biological · Procedure
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
3 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
12
States / cities
Duarte, California • Sacramento, California • San Diego, California + 9 more
Conditions
Atrial Fibrillation, Arterial Hypertension
Interventions
Redo PVI, PVI + RDN
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, New York
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Trandolapril
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Breast Cancer
Interventions
EG12014, Herceptin
Drug
Lead sponsor
EirGenix, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Farmington Hills, Michigan • Canton, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen and Serotonin on Changing Brain Chemistry

NCT01208324
Conditions
Menopause
Interventions
estrogen patch, Amino acids, Placebo Patch, Placebo pills
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
48 Years to 60 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Pramlintide challenge test
Drug
Lead sponsor
Boston University
Other
Eligibility
60 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jamaica Plain, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Screening Protocol for Research Participants

NCT01010620
Conditions
Schizophrenia, Substance Abuse, Cocaine Abuse, Tobacco Use Disorder
Interventions
Various Screening psychiatric and medical assessments
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
523 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
1
States / cities
Catonsville, Maryland
Conditions
Chordoma, Unresectable Malignant Neoplasm
Interventions
Aldoxorubicin Hydrochloride, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, Avelumab, Cetuximab, Cyclophosphamide, SBRT
Biological · Drug · Radiation
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
El Segundo, California
Not listed No phase listed Observational Accepts healthy volunteers

Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout

NCT04125459
Conditions
Gout
Interventions
Joint Biopsy
Procedure
Lead sponsor
Attune Health Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Beverly Hills, California
Conditions
Post-cardiac Surgery, Hyperlactatemia
Interventions
Pyruvate levels
Other
Lead sponsor
University of Florida
Other
Eligibility
Up to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Secondary AML, Myelodysplastic Syndrome (MDS), Secondary MDS, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia (JMML), Paroxysmal Nocturnal Hemoglobinuria (PNH), Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions
Stem Cell Transplantation, Miltenyi Biotec CliniMACS, Systemic chemotherapy and antibodies
Procedure · Device · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Sleep
Interventions
ViSi Mobile device, Sleep enhancement intervention
Device · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Paclitaxel, Carboplatin, Cetuximab, Docetaxel, Cisplatin, Fluorouracil, Radiotherapy (RT), Chemotherapy
Drug · Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Completed Not applicable Interventional Results available

Nutrition and Aerobic Exercise in Chronic Stroke

NCT02043574
Conditions
Stroke
Interventions
Treadmill Exercise, Stretching (control)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • San Antonio, Texas
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Conditions
Leukemia
Interventions
White Blood Cell Transfusion
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Kidney Diseases
Interventions
Renasight
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
31
States / cities
Anchorage, Alaska • Tucson, Arizona • Granada Hills, California + 23 more
Conditions
The Aim of This Study is to Measure Blood Flow Before and After a Block
Interventions
Block performed, LMA placement
Procedure · Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 7 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
Interventions
Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Duarte, California • Irvine, California • La Jolla, California + 9 more
Conditions
Neuroendocrine Tumors
Interventions
Bevacizumab, Temozolomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts
Terminated Not applicable Interventional Results available

Blood Flow Restriction After Meniscus Repair

NCT04436523
Conditions
Meniscus Disorder, Meniscus, Torn Tibial, Meniscus Lesion, Meniscus Tear, Tibial, Atrophy, Muscular
Interventions
Blood flow restriction (Delfi Personalized Tourniquet System), Standard rehabilitation
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California